Company intelligence / Profile preview
Shenzhen Kexing Pharmaceutical
Shenzhen, Guangdong, Chinakexing.com ↗
- Ownership
- Private
- Employees
- ~947
- Development stage
- Other
01
Overview
Kexing Biopharm has multiple recombinant biologics and biosimilars approved and marketed in China, including growth hormone, interferon, and interleukin-2; new assets focusing on cancer cachexia and metabolic diseases are progressing through early clinical and IND stages, with innovative modalities including nanobody-Fc fusions[1][2][11].
- Therapeutic areas
- OncologyInfectious DiseasesEndocrinology
- Modalities
- Recombinant proteinMonoclonal antibodyNanobody therapySmall moleculeBiologicHormoneVaccine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
IQVIA (global clinical development and regulatory strategy partner)[6]
Beyond the preview
Go deeper on Shenzhen Kexing Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Kexing Pharmaceutical.